Literature DB >> 12430936

Non-myeloablative hematopoietic cell transplant for treatment of nonmalignant disorders in children.

Ann E Woolfrey1, Michael A Pulsipher, Rainer Storb.   

Abstract

Hematopoietic stem cell transplantation (HCT) may offer the only curative therapy for certain life-threatening immune deficiency disorders. Conventional HCT poses a risk to patients for severe morbidity, mortality, and late sequelae resulting from myeloablative preparative regimens. This review summarizes the development of nonmyeloablative regimens that have the potential to reduce both short- and long-term risks of HCT. Results of NM-HCT in a small number of patients indicate that this procedure may play an important role in treatment of life-threatening immune deficiencies.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12430936     DOI： 10.1007/bf03165129

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  25 in total

1.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.

Authors:  R Storb; C Yu; J L Wagner; H J Deeg; R A Nash; H P Kiem; W Leisenring; H Shulman
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

2.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

3.  Allogeneic marrow grafting for treatment of aplastic anemia.

Authors:  R Storb; E D Thomas; C D Buckner; R A Clift; F L Johnson; A Fefer; H Glucksberg; E R Giblett; K G Lerner; P Neiman
Journal:  Blood       Date:  1974-02       Impact factor: 22.113

4.  Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings.

Authors:  F Weissinger; B M Sandmaier; D G Maloney; W I Bensinger; T Gooley; R Storb
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

5.  Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.

Authors:  M E Horwitz; A J Barrett; M R Brown; C S Carter; R Childs; J I Gallin; S M Holland; G F Linton; J A Miller; S F Leitman; E J Read; H L Malech
Journal:  N Engl J Med       Date:  2001-03-22       Impact factor: 91.245

6.  Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation.

Authors:  M Sykes; F Preffer; S McAfee; S L Saidman; D Weymouth; D M Andrews; C Colby; R Sackstein; D H Sachs; T R Spitzer
Journal:  Lancet       Date:  1999-05-22       Impact factor: 79.321

Review 7.  Relationship between patterns of engraftment in peripheral blood and immune reconstitution after allogeneic bone marrow transplantation for (severe) combined immunodeficiency.

Authors:  J E van Leeuwen; M J van Tol; A M Joosten; P T Schellekens; R L van den Bergh; J L Waaijer; N J Oudeman-Gruber; C P van der Weijden-Ragas; M T Roos; E J Gerritsen
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

8.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

9.  Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for Immunodeficiency.

Authors:  A Fischer; P Landais; W Friedrich; B Gerritsen; A Fasth; F Porta; A Vellodi; M Benkerrou; J P Jais; M Cavazzana-Calvo
Journal:  Blood       Date:  1994-02-15       Impact factor: 22.113

10.  Bone-marrow transplantation for immunodeficiencies and osteopetrosis: European survey, 1968-1985.

Authors:  A Fischer; C Griscelli; W Friedrich; B Kubanek; R Levinsky; G Morgan; J Vossen; G Wagemaker; P Landais
Journal:  Lancet       Date:  1986-11-08       Impact factor: 79.321
View more
  1 in total

1.  Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts.

Authors:  Matthew M Hsieh; Saskia Langemeijer; Aisha Wynter; Oswald A Phang; Elizabeth M Kang; John F Tisdale
Journal:  Exp Hematol       Date:  2007-07-09       Impact factor: 3.084
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.